Your white blood cells could help cure cancer – Here's how to donate
NCT ID NCT02821806
First seen Jun 25, 2026 · Last updated Aug 18, 2026 · Updated 5 times
Summary
This study collects white blood cells from healthy volunteers to help researchers develop new immune-based cancer treatments. Participants undergo a 4-6 hour procedure called leukapheresis, where a machine separates white cells from the rest of the blood. Donors must be 18 or older, meet health criteria, and can donate every 21 days. The cells are used in the lab to improve T-cell therapies that may one day fight tumors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help scientists develop better T-cell therapies that use a patient's own immune system to fight cancer.
- What could go wrong
- This is a sample-collection study, not a treatment trial. The cells are used for lab research, so there is no direct benefit to participants or guarantee that new therapies will result.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2016
- Expected to finish
-
Feb 2035
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants are healthy volunteers, selected from the general population. Employees may also volunteer per the protocol.@@@
- Ages
-
18 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Age greater than or equal to 18 years old and able to give consent. * Adequate clinical parameters (all of the following): * Afebrile (temperature less than or equal to 37.5 degree C) * Systolic blood pressure less than or equal to180 mmHg * Diastolic blood pressure less than or equal to100 mmHg * Weight greater than or equal to 110 lbs. * Heart rate between 50-100 beats/minute * Adequate bilateral antecubital venous access for a 2 arm apheresis procedure * Females of child-bearing potential should not be pregnant or breast-feeding. * Within 30 days of pheresis donation, donors must be negative for infectious disease work-up: Antibody screen for Hepatitis B, Hepatitis C; HIV, HTLV-I/II, T. cruzi (Chagas agent), West Nile, and syphilis (RPR) * Within 30 days of pheresis donation, donor must have: * Hemoglobin: * Women greater than or equal to 12.5 gm/dL * Men greater than or equal to 13.0 gm/dL * Platelets greater than or equal to 100,000/microliter * Total WBC greater than or equal to 2 K/microliter EXCLUSION CRITERIA: * History of medical illness that in the estimation of the PI or DTM physician precludes donation of PBMCs. * Current psychiatric diagnosis that would compromise compliance with donation or precludes appropriate informed consent. * Presence of any blood transmissible infectious disease that cannot be cleared prior to PBMC donation and poses an unacceptable risk for the recipient. * Active malignancy will exclude the donor. Any history of malignancy will be considered on a case by case basis in accordance with NIH/DTM criteria. * If the participant answers Yes to any initial screening question, the participant will be considered ineligible. * If the participant is deferred according to DTM Cellular Therapy Screening Standard Operating Procedures (SOP), the participant will be considered ineligible.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental brain drug TAK-935 put to the test in healthy volunteers
- Tracing a Low-THC cannabis extract through the human body
- Can a new injection SGB-9768 pass its first safety test?
- Can a new PET tracer reveal the Body's hidden stress?
- Zapping the brain to shift Decision-Making in depression and aging
- Can a new formula make omega-3 and vitamin D3 supplements work better?